 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 02/24/2009 | | | | Nymox Announces New Positive Results at 5 Years After Single Treatment in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
February 24, 2009: Nymox today
announced new positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia
(BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company’s two initial 2003
Phase 1-2 studies of NX-1207. Patients treated with NX-1207 were followed-up on an unselected and as available
basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 64 months after
treatment. |
| 02/18/2009 | | | | Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug
topic: R&D: BPH (enlarged prostate) Treatments
February 18, 2009: Nymox announced today that the Company has recently concluded a positive and productive EOP2 meeting with the FDA concerning the Phase 3 program for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH). The pivotal Phase 3 trials for NX-1207 that are being undertaken will incorporate the specific protocol design recommendations provided to the Company by the FDA. |
| 01/13/2009 | | | | Nymox Releases Positive New Clinical Trial Data on Durability of Response Rates to Company’s BPH Drug NX-1207
topic: R&D: BPH (enlarged prostate) Treatments
January 13, 2009: Nymox announced
today the release of positive new clinical trial data from the Company’s most recent multi-center U.S. studies of NX-1207, indicating durable benefits from Nymox’s innovative drug treatment for benign prostatic hyperplasia (BPH). |
| 01/08/2009 | | | | Third Hand Smoke Recognized as Health Hazard
topic: Tobacco Exposure Tests
January 8, 2009: Nymox offers TobacAlert™, a convenient on-the-spot tool to measure exposure to tobacco products including second hand smoke, and third hand smoke. Third hand smoke is a distinct health hazard,
and refers to tobacco smoke contamination that remains after the cigarette has been extinguished. |
| 12/30/2008 | | | | Nymox Announces $15 Million Equity Financing Commitment
topic: Financial
December 30, 2008) Nymox Pharmaceutical Corporation announced today that the Company has secured a new commitment for $15 million in equity financing from institutional investors. |
| 12/19/2008 | | | | Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
topic: R&D: BPH (enlarged prostate) Treatments
December 19, 2008: Nymox is pleased to announce that recent successful clinical trial results for NX-1207, the
Company’s new drug for benign prostatic hyperplasia (BPH) is featured in the Urology Times, the
widely distributed and most read publication of U.S. urologists. |
| 12/16/2008 | | | | Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug
topic: R&D: BPH (enlarged prostate) Treatments
December 16, 2008: Nymox today
announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company’s
innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can
markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. |
| 12/03/2008 | | | | Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement
topic: R&D: BPH (enlarged prostate) Treatments
December 3, 2008: Nymox reported today positive new data from a recently completed clinical trial of NX-1207, the
Company’s investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptoms of urgent need to urinate, and of frequency of urination. Compared to baseline, symptoms of urgency to urinate were reduced by 47% at 90 days after a single treatment with NX-1207, and this improvement was
maintained in the majority of patients without further treatment at 12 months (41% improvement). Compared to baseline, symptoms of frequency of urination were reduced by 43% at 90
days, and this improvement was also maintained without further treatment at one year in the majority of patients (35% improvement). |
| 11/19/2008 | | | | Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 Investigational Drug for BPH
topic: R&D: BPH (enlarged prostate) Treatments
November 19, 2008: Nymox Pharmaceutical Corporation is pleased to announce the NEXUS-1 and NEXUS-2 Phase 3 clinical trials for NX-1207, the Company's new
drug for benign prostatic hyperplasia (BPH). |
| 11/14/2008 | | | | Nymox Reports Third Quarter 2008 Financial Results
topic: Financial
November 14, 2008: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today its financial results for the third quarter of 2008. |
|